Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03162055 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1119

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease COPD

Interventions

DRUG: Glycopyrronium/Formoterol Fumarate
DRUG: umeclidinium/vilanterol

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]